TNFSF10 and acute myeloid leukemia: Additionally, based on the fact that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce or increase the anti-tumor activity of neutrophil and T cell, Wiersma et al. designed a fusion protein scFvCLL1:TRAIL which can equip neutrophils with high density of TRAIL, as a result, the efficacy against AML cell line and other tumor was enhanced and more importantly, the ADCC activity of neutrophils were significantly increased when anti-tumor monoclonal antibody was combined [44].